Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Psychology’s Julie Exline blogs about the importance of showing gratitude
- Medicine’s Pamela Davis sounds off on advantages of collaborating to launch the Institute of Computational Biology
- Church of the Covenant to hold array of events this Sunday
- Engineering’s Swarup Bhunia earns prestigious IBM Faculty Award
- High school players invited to join softball coaching staff for prospect, skills clinics